灯塔制药公司完成由双点创投领投的1200万美元A轮融资-动脉网

Lighthouse Pharmaceuticals Closes $12 Million Series A Financing Led by Double Point Ventures

CISION 等信源发布 2026-04-28 18:00



可切换为仅中文







NOVATO, Calif.

诺瓦托，加利福尼亚州

，

April 28, 2026

2026年4月28日

/PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel small-molecule therapies for neurodegenerative and inflammatory diseases, today announced the closing of a $12 million Series A financing led by Double Point Ventures, with participation from both new and existing investors..

/PRNewswire/ -- 临床阶段生物制药公司Lighthouse Pharmaceuticals致力于开发治疗神经退行性疾病和炎症性疾病的小分子创新疗法，今天宣布完成了1200万美元的A轮融资，此轮融资由Double Point Ventures领投，新投资者和现有投资者均有参与。

Proceeds from the financing will support advancement of Lighthouse's lead program, LHP588, and continued pipeline expansion. Lighthouse is currently conducting the SPRING clinical trial, a Phase 2 study evaluating LHP588 in patients with

融资所得将用于支持Lighthouse的主要项目LHP588的进展，并继续扩展其研发管线。Lighthouse目前正在开展SPRING临床试验，这是一项评估LHP588在患者中的疗效的二期研究。

P. gingivalis

牙龈卟啉单胞菌

-positive mild to moderate Alzheimer's disease. The trial is also supported by a $49.2 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).

轻度至中度阿尔茨海默病。该试验还得到了美国国立卫生研究院 (NIH) 旗下国家老龄化研究所 (NIA) 提供的 4920 万美元资助的支持。

'Lighthouse is advancing a differentiated approach based on compelling scientific and clinical data. This financing, together with the support from the NIA, gives Lighthouse the resources to efficiently execute the SPRING trial and advance LHP588 toward late-stage development,' said Casey Lynch, Chief Executive Officer of Lighthouse Pharmaceuticals.

“Lighthouse 正在基于令人信服的科学和临床数据推进一种差异化的方法。此次融资加上 NIA 的支持，为 Lighthouse 提供了有效执行 SPRING 试验并推动 LHP588 进入后期开发的资源，”Lighthouse Pharmaceuticals 首席执行官 Casey Lynch 表示。

'By targeting a defined subset of Alzheimer's disease, we aim to bring a more precise and effective therapeutic approach to patients.'.

“通过针对阿尔茨海默病的一个特定子集，我们旨在为患者带来更精确和有效的治疗方法。”

In connection with the financing, Campbell Murray, M.D., partner at Double Point Ventures, will join Lighthouse's Board of Directors. Dr. Murray brings deep experience in life sciences investing, company building, and clinical-stage development strategy.

与融资相关，双点创投 (Double Point Ventures) 合伙人坎贝尔·默里 (Campbell Murray) 医学博士将加入 Lighthouse 董事会。默里博士在生命科学投资、公司组建和临床阶段开发战略方面拥有深厚的经验。

'Lighthouse is pursuing a distinctive and focused approach in Alzheimer's disease,' said Campbell Murray. 'With LHP588, the company is targeting an important and underexplored biological driver in a defined patient population. We believe the SPRING trial has the potential to generate clinically meaningful data and to further establish Lighthouse as an innovative company in neurodegeneration.'.

“Lighthouse 在阿尔茨海默病领域采取了一种独特且专注的方法，”Campbell Murray 表示。“通过 LHP588，公司正针对一个特定患者群体中重要但尚未充分探索的生物学驱动因素。我们相信 SPRING 试验有潜力生成具有临床意义的数据，并进一步确立 Lighthouse 作为神经退行性疾病领域的创新公司地位。”

The SPRING trial is a double-blind placebo-controlled study evaluating LHP588, an oral, once-daily small-molecule therapy targeting

SPRING 试验是一项双盲安慰剂对照研究，评估 LHP588，一种口服的、每日一次的小分子治疗药物，靶向

P. gingivalis

牙龈卟啉单胞菌

, a bacterium associated with periodontal disease and increasingly implicated in Alzheimer's disease pathogenesis and progression. The trial is currently enrolling participants across the United States. Additional information is available at

，一种与牙周病相关并越来越多地被认为与阿尔茨海默病的发病和进展有关的细菌。该试验目前正在美国各地招募参与者。更多信息可访问

www.springclinicaltrial.com

。

About Lighthouse Pharmaceuticals

关于灯塔制药公司

Lighthouse Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for chronic neurodegenerative and inflammatory diseases. The company's lead clinical program is focused on Alzheimer's disease, including the ongoing SPRING clinical trial. For more information, visit .

灯塔制药是一家临床阶段的生物制药公司，致力于开发用于慢性神经退行性疾病和炎症性疾病的小分子疗法。该公司的主要临床项目专注于阿尔茨海默病，包括正在进行的SPRING临床试验。欲了解更多信息，请访问。

www.lighthousepharma.com

。

Research reported in this release is supported by the National Institute on Aging of the National Institutes of Health under Award Number

本发布中报道的研究得到了美国国立卫生研究院下属的国家老龄化研究所的支持，资助编号为

R01AG088524

. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

内容完全由作者负责，不一定代表美国国立卫生研究院的官方观点。

Media Contact

媒体联系人

：

[email protected]